Name (Synonyms) | Correlation |
---|
There is one clinical trial.
International guidelines suggest the administration of empirical broad-spectrum antibiotics for suspected bacterial co-infection in COVID-19 critically ill. However, data on associated respiratory infections is rare and antimicrobial stewardship interventions promoting antibiotic savings are non-existent in this context. The main objectives of the trial are: to evaluate the rate of co-infections among COVID-19 critically ill to evaluate the added value of a a rapid molecular diagnostic tool (FA-PNEU) to detect the presence of co-infecting pathogens in order to rapidly tailor the patient's antibiotic treatment
Description: COVID-19 infections with additional bacteria/viruses identified through FA-PNEU testing
Measure: % of COVID-19 co-infections Time: through study completion, an average of 1 monthDescription: The rapid FA results could allow a fast modification of the empirical antibiotherapy. This percentage will be measured.
Measure: % of antibiotic switches following FA results Time: through study completion, an average of 1 month